Uzi Gileadi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1124390/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Decitabine increases neoantigen and cancer testis antigen expression to enhance T-cell–mediated toxicity against glioblastoma. Neuro-Oncology, 2022, 24, 2093-2106.	1.2	18
2	Hepcidin-Mediated Hypoferremia Disrupts Immune Responses to Vaccination and Infection. Med, 2021, 2, 164-179.e12.	4.4	53
3	PLGA Nanoparticles Co-encapsulating NY-ESO-1 Peptides and IMM60 Induce Robust CD8 and CD4 T Cell and B Cell Responses. Frontiers in Immunology, 2021, 12, 641703.	4.8	21
4	Chromatin accessibility governs the differential response of cancer and TÂcells to arginine starvation. Cell Reports, 2021, 35, 109101.	6.4	20
5	Generation and characterization of HLA-A2 transgenic mice expressing the human TCR 1G4 specific for the HLA-A2 restricted NY-ESO-1 ₁₅₇₋₁₆₅ tumor-specific peptide. , 2021, 9, e002544.		9
6	ADGRL4/ELTD1 Expression in Breast Cancer Cells Induces Vascular Normalization and Immune Suppression. Molecular Cancer Research, 2021, 19, 1957-1969.	3.4	4
7	Assessing the safety, tolerability and efficacy of PLGA-based immunomodulatory nanoparticles in patients with advanced NY-ESO-1-positive cancers: a first-in-human phase I open-label dose-escalation study protocol. BMJ Open, 2021, 11, e050725.	1.9	21
8	Cell identity and nucleo-mitochondrial genetic context modulate OXPHOS performance and determine somatic heteroplasmy dynamics. Science Advances, 2020, 6, eaba5345.	10.3	31
9	Structural and functional characterization of C0021158, a high-affinity monoclonal antibody that inhibits Arginase 2 function via a novel non-competitive mechanism of action. MAbs, 2020, 12, 1801230.	5.2	2
10	Nanovaccine administration route is critical to obtain pertinent iNKt cell help for robust anti-tumor T and B cell responses. Oncolmmunology, 2020, 9, 1738813.	4.6	37
11	Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model. British Journal of Cancer, 2020, 123, 1089-1100.	6.4	51
12	Enhanced Immunogenicity of Mitochondrial-Localized Proteins in Cancer Cells. Cancer Immunology Research, 2020, 8, 685-697.	3.4	6
13	Sterile activation of invariant natural killer T cells by ER-stressed antigen-presenting cells. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 23671-23681.	7.1	21
14	NOD2 and TLR2 Signal via TBK1 and PI31 to Direct Cross-Presentation and CD8 T Cell Responses. Frontiers in Immunology, 2019, 10, 958.	4.8	31
15	Dendritic cells enter lymph vessels by hyaluronan-mediated docking to the endothelial receptor LYVE-1. Nature Immunology, 2017, 18, 762-770.	14.5	147
16	Activation of Human Mucosal-Associated Invariant T Cells Induces CD40L-Dependent Maturation of Monocyte-Derived and Primary Dendritic Cells. Journal of Immunology, 2017, 199, 2631-2638.	0.8	96
17	Nutritional Stress Induced by Tryptophan-Degrading Enzymes Results in ATF4-Dependent Reprogramming of the Amino Acid Transporter Profile in Tumor Cells. Cancer Research, 2016, 76, 6193-6204.	0.9	45
18	Nonâ€glycosidic compounds can stimulate both human and mouse <i>i</i> NKT cells. European Journal of Immunology, 2016, 46, 1224-1234.	2.9	14

Uzi Gileadi

#	Article	IF	CITATIONS
19	Co-delivery of PLGA encapsulated invariant NKT cell agonist with antigenic protein induce strong T cell-mediated antitumor immune responses. Oncolmmunology, 2016, 5, e1068493.	4.6	68
20	Effect of epitope flanking residues on the presentation of N-terminal cytotoxic T lymphocyte epitopes. European Journal of Immunology, 1999, 29, 2213-2222.	2.9	27
21	Structural model of ATP-binding proteing associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature, 1990, 346, 362-365.	27.8	1,174